PT1680403T - Análogos de deoxinojirimicina e seus usos como inibidores de glucosilceramidase - Google Patents

Análogos de deoxinojirimicina e seus usos como inibidores de glucosilceramidase

Info

Publication number
PT1680403T
PT1680403T PT47936851T PT04793685T PT1680403T PT 1680403 T PT1680403 T PT 1680403T PT 47936851 T PT47936851 T PT 47936851T PT 04793685 T PT04793685 T PT 04793685T PT 1680403 T PT1680403 T PT 1680403T
Authority
PT
Portugal
Prior art keywords
glucosylceramidase
inhibitors
deoxynojirimycin analogues
deoxynojirimycin
analogues
Prior art date
Application number
PT47936851T
Other languages
English (en)
Portuguese (pt)
Inventor
Maria Franciscus Gerardus Aerts Johannes
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PT1680403T publication Critical patent/PT1680403T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT47936851T 2003-10-29 2004-10-29 Análogos de deoxinojirimicina e seus usos como inibidores de glucosilceramidase PT1680403T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03078395A EP1528056A1 (en) 2003-10-29 2003-10-29 Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors

Publications (1)

Publication Number Publication Date
PT1680403T true PT1680403T (pt) 2016-09-07

Family

ID=34400526

Family Applications (1)

Application Number Title Priority Date Filing Date
PT47936851T PT1680403T (pt) 2003-10-29 2004-10-29 Análogos de deoxinojirimicina e seus usos como inibidores de glucosilceramidase

Country Status (14)

Country Link
US (1) US7528153B2 (enExample)
EP (2) EP1528056A1 (enExample)
JP (2) JP5016925B2 (enExample)
AU (1) AU2004284012B2 (enExample)
CA (1) CA2551060C (enExample)
CY (1) CY1118191T1 (enExample)
DK (1) DK1680403T3 (enExample)
ES (1) ES2594356T3 (enExample)
HU (1) HUE029637T2 (enExample)
IL (1) IL175260A0 (enExample)
PL (1) PL1680403T3 (enExample)
PT (1) PT1680403T (enExample)
SI (1) SI1680403T1 (enExample)
WO (1) WO2005040118A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004283631A1 (en) * 2003-10-29 2005-05-06 Genzyme Corporation Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
EP1528056A1 (en) 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
WO2005092334A2 (en) * 2004-03-25 2005-10-06 David Priestman Use of n-substituted imino sugars for appetite suppression
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
FR2887549B1 (fr) * 2005-06-23 2009-07-10 Centre Nat Rech Scient Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation
FR2894482A1 (fr) * 2005-12-14 2007-06-15 Galderma Sa Utilisation d'une composition comprenant une association d'hydroquinone,d'acetonide de fluocinolone et de tretinoine, dans le traitement d'l'hyperpigmentation de la peau suite au psoriasis ou a l'eczema
CA2650311A1 (en) * 2006-04-24 2007-11-01 Academisch Medisch Centrum Improved treatment of cystic fibrosis
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
EP2594563B1 (en) 2007-05-31 2018-07-18 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
CA2701649C (en) 2007-10-05 2016-05-24 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US8497122B2 (en) 2008-04-11 2013-07-30 Washington University Biomarkers for Niemann-pick C disease and related disorders
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
CN102271678B (zh) 2008-10-03 2017-06-30 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合成酶抑制剂
EP2398500B1 (en) * 2009-02-20 2019-03-13 2-BBB Medicines B.V. Glutathione-based drug delivery system
CA2793276A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
CN102740852A (zh) * 2009-12-07 2012-10-17 牛津大学之校长及学者 用于抑制破骨细胞形成和/或破骨细胞活化的n-取代的脱氧野尻霉素化合物
US8981083B2 (en) 2010-05-14 2015-03-17 Dana Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
ES2371398B1 (es) * 2010-06-04 2013-05-20 Bioglane, S.L.N.E. Uso de un iminoazúcar como inhibidor de la adherencia a células epiteliales.
EP2533051A1 (en) 2011-06-06 2012-12-12 Centogene GmbH Method for the diagnosis of Gaucher's disease
US9804152B1 (en) * 2012-08-15 2017-10-31 The Procter & Gamble Company Human ex vivo skin model and its use in methods of identifying modulators of skin inflammation
US9623016B2 (en) 2013-03-15 2017-04-18 Emergent Virology Llc Antibacterial compounds
US20160075651A1 (en) * 2013-05-02 2016-03-17 Unither Virology, Llc Glycolipid inhibition using iminosugars
US20160061849A1 (en) * 2013-05-02 2016-03-03 Unither Virology, Llc Lipidomic biomarkers
EP3024327B1 (en) 2013-07-25 2019-09-04 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
RU2722179C2 (ru) 2014-02-28 2020-05-28 Тэнша Терапеутикс, Инк. Лечение состояний, ассоциированных с гиперинсулинемией
WO2015147639A1 (en) 2014-03-27 2015-10-01 Academisch Medisch Centrum N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
CA2955074A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
JP2017525759A (ja) 2014-08-08 2017-09-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジヒドロプテリジノン誘導体およびその使用
EP3212654B1 (en) 2014-10-27 2020-04-08 Tensha Therapeutics, Inc. Bromodomain inhibitors
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
BR112018004618A2 (pt) 2015-09-11 2018-09-25 Dana-Farber Cancer Institute, Inc. ciano tienotriazoldiazepinas e usos das mesmas
CA2996977A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
US10913752B2 (en) 2015-11-25 2021-02-09 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
US20220257604A1 (en) * 2019-03-08 2022-08-18 University Of Virginia Patent Foundation Compositions and methods for modulating viral infections by regulating glucosylceramides
PH12022552955A1 (en) * 2020-05-07 2024-02-26 Alectos Therapeutics Inc Non-lysosomal glucosylceramidase inhibitors and uses thereof
WO2022227287A1 (zh) * 2021-04-25 2022-11-03 中南大学 Dnj及其衍生物在制备预防和/或治疗肺动脉高压药物中的应用
CN118459393B (zh) * 2024-04-29 2025-11-28 中国科学院成都生物研究所 一类具有α-葡萄糖苷酶抑制活性的D-木糖衍生物及制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2504000B2 (ja) 1986-09-02 1996-06-05 日本新薬株式会社 グルコシルモラノリン誘導体
JP4564108B2 (ja) * 1996-07-15 2010-10-20 ジェンザイム コーポレーション デオキシノジリマイシン誘導体及び該誘導体のグルコシルセラミダーゼ阻害剤としての用途
BR9902585A (pt) 1999-02-11 2000-09-26 Claudio Cerqueira Lopes Um novo processo de sìntese de aza-açúcares com atividade biológica
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
US6235737B1 (en) 2000-01-25 2001-05-22 Peter Styczynski Reduction of hair growth
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
JP4575156B2 (ja) * 2002-07-17 2010-11-04 アクテリオン ファーマシューティカルズ リミテッド グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体
ES2393919T3 (es) * 2002-07-17 2013-01-02 Actelion Pharmaceuticals Ltd. Derivados de PIPERIDINETRIOL como inhibidores de GLUCOSILCERAMIDA SINTASA
GB0229476D0 (en) 2002-12-17 2003-01-22 Oxford Glycosciences Uk Ltd Novel process
EP1528056A1 (en) 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
AU2004283631A1 (en) * 2003-10-29 2005-05-06 Genzyme Corporation Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
WO2005063706A1 (en) 2003-12-23 2005-07-14 Macrozyme Dnm B.V. Synthesis of nojirimycins
EP2932982B1 (en) 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives

Also Published As

Publication number Publication date
WO2005040118A1 (en) 2005-05-06
JP5016925B2 (ja) 2012-09-05
CA2551060C (en) 2012-08-28
EP1528056A1 (en) 2005-05-04
AU2004284012A1 (en) 2005-05-06
EP1680403A1 (en) 2006-07-19
AU2004284012B2 (en) 2010-06-17
CY1118191T1 (el) 2017-06-28
US20070066581A1 (en) 2007-03-22
PL1680403T3 (pl) 2017-08-31
CA2551060A1 (en) 2005-05-06
SI1680403T1 (sl) 2017-01-31
JP2012180353A (ja) 2012-09-20
ES2594356T3 (es) 2016-12-19
US7528153B2 (en) 2009-05-05
HUE029637T2 (en) 2017-03-28
JP5730808B2 (ja) 2015-06-10
IL175260A0 (en) 2006-09-05
JP2007509926A (ja) 2007-04-19
DK1680403T3 (en) 2016-09-26
EP1680403B1 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
IL175260A0 (en) Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
AU2003298514A8 (en) Methods and compositions using cholinesterase inhibitors
PL372814A1 (en) Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
AP2089A (en) Compositions and methods for combination antiviraltherapy
EP1633718A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-S
EG25482A (en) Inhibitors
GB0411940D0 (en) Methods and compositions
EP1701725A4 (en) PROCESS AND COMPOSITIONS
IL187620A0 (en) 17??-hsd1 and sts inhibitors
PT1592686E (pt) Inibidores de girase e suas utilizações
AU2003299034A8 (en) Transdermal compositions
AU2003256805A8 (en) Compounds compositions and methods
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2003275268A8 (en) Hemostatic compositions and methods
EP1532133A4 (en) NF-: B INHIBITORS
EP1684771A4 (en) COMPOSITION AND METHOD
ZA200502843B (en) Methods and compositions for providing glutamine
AU2003299901A8 (en) Thrombin inhibitors
EP1506778A4 (en) TGF-a EXPRESSION HEMMER
EP1765373A4 (en) OZONIZED PHARMACEUTICAL COMPOSITION AND METHOD THEREOF
AU2003268078A8 (en) Levothyroxine compositions and methods
AU2003222258A8 (en) Inhibitors for use in hemostasis
AU2003245524A8 (en) Cryosurgery compositions and methods
AU2003298035A8 (en) Compositions and methods for inhibiting malaria protease falcipain-2
AU2003238948A8 (en) Caspase-1 inhibitors and methods for their use